for people ages 18 years and up (full criteria)
at UC Irvine
study started
estimated completion



The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.

Official Title

PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study


Study Design:

Up to 60 subjects are expected to be enrolled after discontinuation from the SOLAR clinical study (MRG106-11-201). Cobomarsen will be administered in the clinic by 2-hr intravenous infusion on Days 1, 3, 5 and 8, and weekly thereafter. Treatment will continue until the subject becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated.


Cutaneous T-Cell Lymphoma/Mycosis Fungoides PRISM Cutaneous T-cell Lymphoma CTCL Mycosis Fungoides Lymphoma Lymphoma, T-cell Lymphoma, T-cell, cutaneous Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neoplasms MicroRNAs Mycoses Cobomarsen


You can join if…

Open to people ages 18 years and up

  • Must have participated in the comparator arm of the SOLAR clinical trial and completed the study (confirmed disease progression).

You CAN'T join if...

  • Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented history of B2 and/or B2 staging at screening.
  • Evidence of large cell transformation.
  • Visceral involvement related to MF at screening.
  • Unresolved toxicities from prior vorinostat treatment, defined as having not resolved to CTCAE v5.0 grade 0 or 1.
  • Any CTCL systemic therapy after completion of the SOLAR study and prior to Day 1 for PRISM.


  • Chao Family Comprehensive Cancer Center at University of California-Irvine
    Orange California 92868 United States
  • City of Hope
    Duarte California 91010 United States


accepting new patients by invitation only
Start Date
Completion Date
miRagen Therapeutics, Inc.
Phase 2
Study Type
Last Updated